EA
ALXN

Edge Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Edge Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$0 Hold
5
– – ﹤0.01% 938
2018
Q1 		$0 Buy
+5
New +$598 ﹤0.01% 979
2017
Q4 		– Sell
-3
Closed – – 987
2017
Q3 		$0 Hold
3
– – ﹤0.01% 1023
2017
Q2 		$0 Hold
3
– – ﹤0.01% 1048
2017
Q1 		$0 Hold
3
– – ﹤0.01% 1018
2016
Q4 		$0 Buy
+3
New +$367 ﹤0.01% 900

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Edge Advisors's ALXN Position: Q2 2018 in Review

Edge Advisors held its Alexion Pharmaceuticals (ALXN) position steady in Q2 2018 at 5 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Edge Advisors first reported a position in ALXN in Q4 2016 and has held it in 6 quarters since. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Edge Advisors held 5 shares of Alexion Pharmaceuticals worth $0 as of Q2 2018.
  • Edge Advisors left its Alexion Pharmaceuticals share count unchanged in Q2 2018.
  • Alexion Pharmaceuticals made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #938 holding.
  • Edge Advisors first reported a position in Alexion Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.